Bio-rad Laboratories Inc (BIO) Q3 2014 10-Q Quarterly Earnings

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q3 2014 10-Q quarterly report on Nov 7, 2014 for the quarter ended Sep 30, 2014.

AI summary of MD&A and risk factor updates

Third-quarter revenue $530.6M, up 5.1% YoY from $505.1M
Gross margin 54.4% vs 56.3% YoY, net margin 2.2% vs (1.4)%
Best segment: Life Science revenue $172.8M, up 6.1%; Clinical Diagnostics $354.7M, up 4.7%
Nine-month operating cash flow $233.1M vs $98.6M; capital expenditures $80.9M
Cash, equivalents and short-term investments $702.6M; ERP implementation could exceed $300M over four or more years

FCPA settlement: $14.4M DOJ penalty, $40.7M SEC disgorgement, with two-year compliance obligations
China regulatory review: Shanghai AIC imposed $0.3M penalty and disgorgement, while import-practice review remains open
Internal controls: material weakness still existed at September 30, 2014, risking financial misstatements and reporting failures
International exposure: foreign subsidiaries generated 67% of nine-month sales, with currency and geopolitical risks affecting results
Debt burden: $437.2M outstanding debt, restricting flexibility and increasing refinancing and covenant risks

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.